OpenAI Acquires Pharma Co Orchestra Bio to Build AI Agents for Drug Development
OpenAI has acquired biopharma startup Orchestra Bio to build specialized AI agents aimed at accelerating drug discovery and development.
OpenAI has acquired biopharma startup Orchestra Bio to build specialized AI agents aimed at accelerating drug discovery and development. As part of the transaction, Orchestra Bio's team will join OpenAI to integrate deep domain expertise in biology and chemistry directly into AI workflows. The acquisition underscores OpenAI's strategy to expand beyond general-purpose models into high-impact scientific fields, enabling automated data analysis and predictive modeling for complex pharmaceutical research.